News NFL Biosciences

Stocks

ALNFL

FR0014003XT0

Biotechnology & Medical Research

Market Closed - Euronext Paris 03:55:00 31/10/26 am AEDT			5-day change	1st Jan Change
0.4500 ^EUR	+12.22%		-15.09%	-61.80%

23/10	NFL Biosciences SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
22/10	NFL Biosciences Gets Regulatory Approvals to Begin Phase 2 Nicotine Cessation Trial for NFL-102	MT

All News

Mentions Relevance

30/10	NFL Biosciences will participate in the BIO-Europe 2026 conference to continue discussions with potential partners regarding NFL-101 and NFL-102	BU
23/10	NFL Biosciences Reports Its 2026 Half-Year Results and Progress With Its Two Immunotherapies for Smoking and Nicotine Cessation	BU
23/10	NFL Biosciences SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
22/10	NFL Biosciences Gets Regulatory Approvals to Begin Phase 2 Nicotine Cessation Trial for NFL-102	MT
22/10	Nfl Biosciences Receives Regulatory Approval to Begin Its Phase 2 Tonic Study Evaluating Nfl-102 for Smoking and Nicotine Cessation	CI
22/10	NFL Biosciences Receives Regulatory Approval to Begin Its Phase 2 TONIC Trial for Smoking and Nicotine Cessation	BU
06/10	NFL Biosciences: Progress Update Ahead of Upcoming Value-Creating Milestones for Its Two Clinical Programs in Smoking Cessation	BU
06/10	NFL Biosciences Provides Progress Update on NFL-101 and NFL-102 Clinical Programs in Smoking Cessation	CI
08/09	NFL Biosciences to Present Its Personalized Medicine Approach to Smoking Cessation at the 20th Congress of the Société Francophone de Tabacologie	BU
29/07	NFL Biosciences Submits an Application for Authorization of the Phase 2 TONIC Clinical Trial Evaluating NFL-102 in Smoking Cessation	BU
29/07	NFL Biosciences Submits Application For Authorization Of The Phase 2 Tonic Clinical Trial Evaluating NFL-102 In Smoking Cessation	CI
08/07	Nfl Biosciences Presents Three Scientific Communications on Nfl-101 and Nfl-102 At 2026 Srnt-Europe Conference	CI
08/07	International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102	BU
01/07	NFL Biosciences Successfully Manufactures GMP Clinical Batch Of NFL-102 And Validates Industrial Production Chain	CI
01/07	NFL Biosciences validates industrial-scale production of NFL-102 for smoking cessation
01/07	NFL Biosciences Announces the Successful Manufacturing of a GMP Clinical Batch of NFL-102 and Validates Its Industrial Production Chain	BU
02/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	CI
02/06	NFL Biosciences validates breakthrough in personalized medicine
02/06	NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation	BU
26/05	NFL Biosciences to File Patent Application for Smoking Cessation Drug-linked Biomarker	MT
26/05	NFL Biosciences files new patent application
26/05	NFL Biosciences Is Strengthening Its Personalized Medicine Approach to Smoking Cessation With a New Patent Application	BU
26/05	NFL Biosciences Files Patent Application Protecting Predictive Efficacy Biomarker Associated With NFL-101	CI
12/05	NFL Biosciences SA Clarifies Objectives And Evaluation Criteria For Predictive Biomarker Associated With NFL-101	CI
12/05	NFL Biosciences Clarifies the Objectives and Evaluation Criteria for a Predictive Biomarker Associated With NFL-101	BU